CN1225244C - 含吲哒帕胺和β兼α阻滞剂的复方降压制剂 - Google Patents
含吲哒帕胺和β兼α阻滞剂的复方降压制剂 Download PDFInfo
- Publication number
- CN1225244C CN1225244C CN 03150882 CN03150882A CN1225244C CN 1225244 C CN1225244 C CN 1225244C CN 03150882 CN03150882 CN 03150882 CN 03150882 A CN03150882 A CN 03150882A CN 1225244 C CN1225244 C CN 1225244C
- Authority
- CN
- China
- Prior art keywords
- indopamide
- group
- beta
- retarder
- blood pressure
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
- 238000002360 preparation method Methods 0.000 title claims abstract description 62
- 239000002131 composite material Substances 0.000 title claims description 25
- 230000036772 blood pressure Effects 0.000 title abstract description 30
- 229960004569 indapamide Drugs 0.000 title abstract description 4
- NDDAHWYSQHTHNT-UHFFFAOYSA-N indapamide Chemical compound CC1CC2=CC=CC=C2N1NC(=O)C1=CC=C(Cl)C(S(N)(=O)=O)=C1 NDDAHWYSQHTHNT-UHFFFAOYSA-N 0.000 title abstract description 4
- SGUAFYQXFOLMHL-UHFFFAOYSA-N 2-hydroxy-5-{1-hydroxy-2-[(4-phenylbutan-2-yl)amino]ethyl}benzamide Chemical compound C=1C=C(O)C(C(N)=O)=CC=1C(O)CNC(C)CCC1=CC=CC=C1 SGUAFYQXFOLMHL-UHFFFAOYSA-N 0.000 claims abstract description 29
- 229960001632 labetalol Drugs 0.000 claims abstract description 26
- 239000002934 diuretic Substances 0.000 claims abstract description 20
- 230000001882 diuretic effect Effects 0.000 claims abstract description 20
- 230000003276 anti-hypertensive effect Effects 0.000 claims description 36
- 239000002160 alpha blocker Substances 0.000 claims description 33
- 239000002775 capsule Substances 0.000 claims description 15
- 239000002552 dosage form Substances 0.000 claims description 4
- 239000003937 drug carrier Substances 0.000 claims description 2
- METKIMKYRPQLGS-GFCCVEGCSA-N (R)-atenolol Chemical group CC(C)NC[C@@H](O)COC1=CC=C(CC(N)=O)C=C1 METKIMKYRPQLGS-GFCCVEGCSA-N 0.000 abstract description 29
- 229960002274 atenolol Drugs 0.000 abstract description 26
- VHYCDWMUTMEGQY-UHFFFAOYSA-N bisoprolol Chemical compound CC(C)NCC(O)COC1=CC=C(COCCOC(C)C)C=C1 VHYCDWMUTMEGQY-UHFFFAOYSA-N 0.000 abstract description 26
- 229960002781 bisoprolol Drugs 0.000 abstract description 24
- 230000000694 effects Effects 0.000 abstract description 23
- 239000003814 drug Substances 0.000 abstract description 22
- 150000001875 compounds Chemical class 0.000 abstract description 19
- IUBSYMUCCVWXPE-UHFFFAOYSA-N metoprolol Chemical compound COCCC1=CC=C(OCC(O)CNC(C)C)C=C1 IUBSYMUCCVWXPE-UHFFFAOYSA-N 0.000 abstract description 15
- 229960002237 metoprolol Drugs 0.000 abstract description 15
- AQHHHDLHHXJYJD-UHFFFAOYSA-N propranolol Chemical compound C1=CC=C2C(OCC(O)CNC(C)C)=CC=CC2=C1 AQHHHDLHHXJYJD-UHFFFAOYSA-N 0.000 abstract description 14
- 239000000203 mixture Substances 0.000 abstract description 11
- 229960003712 propranolol Drugs 0.000 abstract description 7
- 229940079593 drug Drugs 0.000 abstract description 3
- 230000002195 synergetic effect Effects 0.000 abstract description 2
- 229960004195 carvedilol Drugs 0.000 abstract 1
- NPAKNKYSJIDKMW-UHFFFAOYSA-N carvedilol Chemical compound COC1=CC=CC=C1OCCNCC(O)COC1=CC=CC2=NC3=CC=C[CH]C3=C12 NPAKNKYSJIDKMW-UHFFFAOYSA-N 0.000 abstract 1
- JZUFKLXOESDKRF-UHFFFAOYSA-N Chlorothiazide Chemical compound C1=C(Cl)C(S(=O)(=O)N)=CC2=C1NCNS2(=O)=O JZUFKLXOESDKRF-UHFFFAOYSA-N 0.000 description 33
- 239000002876 beta blocker Substances 0.000 description 25
- 229940097320 beta blocking agent Drugs 0.000 description 25
- 229960002003 hydrochlorothiazide Drugs 0.000 description 24
- 238000011282 treatment Methods 0.000 description 19
- 230000003203 everyday effect Effects 0.000 description 18
- 206010020772 Hypertension Diseases 0.000 description 17
- 230000009467 reduction Effects 0.000 description 16
- -1 labetalol compound Chemical class 0.000 description 14
- 238000011287 therapeutic dose Methods 0.000 description 9
- 230000035487 diastolic blood pressure Effects 0.000 description 7
- 239000008280 blood Substances 0.000 description 6
- 210000004369 blood Anatomy 0.000 description 6
- 238000011125 single therapy Methods 0.000 description 6
- 230000001225 therapeutic effect Effects 0.000 description 6
- DNXIKVLOVZVMQF-UHFFFAOYSA-N (3beta,16beta,17alpha,18beta,20alpha)-17-hydroxy-11-methoxy-18-[(3,4,5-trimethoxybenzoyl)oxy]-yohimban-16-carboxylic acid, methyl ester Natural products C1C2CN3CCC(C4=CC=C(OC)C=C4N4)=C4C3CC2C(C(=O)OC)C(O)C1OC(=O)C1=CC(OC)=C(OC)C(OC)=C1 DNXIKVLOVZVMQF-UHFFFAOYSA-N 0.000 description 5
- LCQMZZCPPSWADO-UHFFFAOYSA-N Reserpilin Natural products COC(=O)C1COCC2CN3CCc4c([nH]c5cc(OC)c(OC)cc45)C3CC12 LCQMZZCPPSWADO-UHFFFAOYSA-N 0.000 description 5
- QEVHRUUCFGRFIF-SFWBKIHZSA-N Reserpine Natural products O=C(OC)[C@@H]1[C@H](OC)[C@H](OC(=O)c2cc(OC)c(OC)c(OC)c2)C[C@H]2[C@@H]1C[C@H]1N(C2)CCc2c3c([nH]c12)cc(OC)cc3 QEVHRUUCFGRFIF-SFWBKIHZSA-N 0.000 description 5
- 239000000890 drug combination Substances 0.000 description 5
- 238000004519 manufacturing process Methods 0.000 description 5
- BJOIZNZVOZKDIG-MDEJGZGSSA-N reserpine Chemical compound O([C@H]1[C@@H]([C@H]([C@H]2C[C@@H]3C4=C([C]5C=CC(OC)=CC5=N4)CCN3C[C@H]2C1)C(=O)OC)OC)C(=O)C1=CC(OC)=C(OC)C(OC)=C1 BJOIZNZVOZKDIG-MDEJGZGSSA-N 0.000 description 5
- 229960003147 reserpine Drugs 0.000 description 5
- MDMGHDFNKNZPAU-UHFFFAOYSA-N roserpine Natural products C1C2CN3CCC(C4=CC=C(OC)C=C4N4)=C4C3CC2C(OC(C)=O)C(OC)C1OC(=O)C1=CC(OC)=C(OC)C(OC)=C1 MDMGHDFNKNZPAU-UHFFFAOYSA-N 0.000 description 5
- 238000002560 therapeutic procedure Methods 0.000 description 5
- 239000002083 C09CA01 - Losartan Substances 0.000 description 4
- 239000002220 antihypertensive agent Substances 0.000 description 4
- 229940127088 antihypertensive drug Drugs 0.000 description 4
- VQKLRVZQQYVIJW-UHFFFAOYSA-N dihydralazine Chemical compound C1=CC=C2C(NN)=NN=C(NN)C2=C1 VQKLRVZQQYVIJW-UHFFFAOYSA-N 0.000 description 4
- 229960002877 dihydralazine Drugs 0.000 description 4
- GBXSMTUPTTWBMN-XIRDDKMYSA-N enalapril Chemical compound C([C@@H](C(=O)OCC)N[C@@H](C)C(=O)N1[C@@H](CCC1)C(O)=O)CC1=CC=CC=C1 GBXSMTUPTTWBMN-XIRDDKMYSA-N 0.000 description 4
- 230000001077 hypotensive effect Effects 0.000 description 4
- QSHDDOUJBYECFT-UHFFFAOYSA-N mercury Chemical compound [Hg] QSHDDOUJBYECFT-UHFFFAOYSA-N 0.000 description 4
- 229910052753 mercury Inorganic materials 0.000 description 4
- 230000035488 systolic blood pressure Effects 0.000 description 4
- XPCFTKFZXHTYIP-PMACEKPBSA-N Benazepril Chemical compound C([C@@H](C(=O)OCC)N[C@@H]1C(N(CC(O)=O)C2=CC=CC=C2CC1)=O)CC1=CC=CC=C1 XPCFTKFZXHTYIP-PMACEKPBSA-N 0.000 description 3
- 208000007530 Essential hypertension Diseases 0.000 description 3
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 3
- 208000019025 Hypokalemia Diseases 0.000 description 3
- 208000004880 Polyuria Diseases 0.000 description 3
- 102100028255 Renin Human genes 0.000 description 3
- 108090000783 Renin Proteins 0.000 description 3
- 229960002576 amiloride Drugs 0.000 description 3
- XSDQTOBWRPYKKA-UHFFFAOYSA-N amiloride Chemical compound NC(=N)NC(=O)C1=NC(Cl)=C(N)N=C1N XSDQTOBWRPYKKA-UHFFFAOYSA-N 0.000 description 3
- 210000000436 anus Anatomy 0.000 description 3
- 230000000740 bleeding effect Effects 0.000 description 3
- 210000004204 blood vessel Anatomy 0.000 description 3
- 238000009472 formulation Methods 0.000 description 3
- 239000008103 glucose Substances 0.000 description 3
- 208000010125 myocardial infarction Diseases 0.000 description 3
- 208000024896 potassium deficiency disease Diseases 0.000 description 3
- 238000011160 research Methods 0.000 description 3
- 238000012353 t test Methods 0.000 description 3
- SGTNSNPWRIOYBX-UHFFFAOYSA-N 2-(3,4-dimethoxyphenyl)-5-{[2-(3,4-dimethoxyphenyl)ethyl](methyl)amino}-2-(propan-2-yl)pentanenitrile Chemical compound C1=C(OC)C(OC)=CC=C1CCN(C)CCCC(C#N)(C(C)C)C1=CC=C(OC)C(OC)=C1 SGTNSNPWRIOYBX-UHFFFAOYSA-N 0.000 description 2
- QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 2
- 206010002383 Angina Pectoris Diseases 0.000 description 2
- 206010008190 Cerebrovascular accident Diseases 0.000 description 2
- 108010061435 Enalapril Proteins 0.000 description 2
- 206010019233 Headaches Diseases 0.000 description 2
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 2
- UWWDHYUMIORJTA-HSQYWUDLSA-N Moexipril Chemical compound C([C@@H](C(=O)OCC)N[C@@H](C)C(=O)N1[C@@H](CC2=CC(OC)=C(OC)C=C2C1)C(O)=O)CC1=CC=CC=C1 UWWDHYUMIORJTA-HSQYWUDLSA-N 0.000 description 2
- 208000006011 Stroke Diseases 0.000 description 2
- FNYLWPVRPXGIIP-UHFFFAOYSA-N Triamterene Chemical compound NC1=NC2=NC(N)=NC(N)=C2N=C1C1=CC=CC=C1 FNYLWPVRPXGIIP-UHFFFAOYSA-N 0.000 description 2
- 208000005946 Xerostomia Diseases 0.000 description 2
- 230000002181 anti-sympathetic effect Effects 0.000 description 2
- 229960004530 benazepril Drugs 0.000 description 2
- HDWIHXWEUNVBIY-UHFFFAOYSA-N bendroflumethiazidum Chemical compound C1=C(C(F)(F)F)C(S(=O)(=O)N)=CC(S(N2)(=O)=O)=C1NC2CC1=CC=CC=C1 HDWIHXWEUNVBIY-UHFFFAOYSA-N 0.000 description 2
- 230000036471 bradycardia Effects 0.000 description 2
- 208000006218 bradycardia Diseases 0.000 description 2
- 230000008602 contraction Effects 0.000 description 2
- 238000007796 conventional method Methods 0.000 description 2
- 208000029078 coronary artery disease Diseases 0.000 description 2
- 230000003247 decreasing effect Effects 0.000 description 2
- 206010012601 diabetes mellitus Diseases 0.000 description 2
- FHIVAFMUCKRCQO-UHFFFAOYSA-N diazinon Chemical compound CCOP(=S)(OCC)OC1=CC(C)=NC(C(C)C)=N1 FHIVAFMUCKRCQO-UHFFFAOYSA-N 0.000 description 2
- 208000002173 dizziness Diseases 0.000 description 2
- 206010013781 dry mouth Diseases 0.000 description 2
- 229960000873 enalapril Drugs 0.000 description 2
- 230000005284 excitation Effects 0.000 description 2
- 239000013022 formulation composition Substances 0.000 description 2
- 231100000869 headache Toxicity 0.000 description 2
- 230000036541 health Effects 0.000 description 2
- 229940090022 hyzaar Drugs 0.000 description 2
- 210000003734 kidney Anatomy 0.000 description 2
- 229960004773 losartan Drugs 0.000 description 2
- KJJZZJSZUJXYEA-UHFFFAOYSA-N losartan Chemical compound CCCCC1=NC(Cl)=C(CO)N1CC1=CC=C(C=2C(=CC=CC=2)C=2[N]N=NN=2)C=C1 KJJZZJSZUJXYEA-UHFFFAOYSA-N 0.000 description 2
- 230000007246 mechanism Effects 0.000 description 2
- 230000002107 myocardial effect Effects 0.000 description 2
- 210000005036 nerve Anatomy 0.000 description 2
- 230000002265 prevention Effects 0.000 description 2
- 230000002040 relaxant effect Effects 0.000 description 2
- 239000011734 sodium Substances 0.000 description 2
- 229910052708 sodium Inorganic materials 0.000 description 2
- LXMSZDCAJNLERA-ZHYRCANASA-N spironolactone Chemical compound C([C@@H]1[C@]2(C)CC[C@@H]3[C@@]4(C)CCC(=O)C=C4C[C@H]([C@@H]13)SC(=O)C)C[C@@]21CCC(=O)O1 LXMSZDCAJNLERA-ZHYRCANASA-N 0.000 description 2
- 230000002889 sympathetic effect Effects 0.000 description 2
- 230000002792 vascular Effects 0.000 description 2
- BFNXYSZBURSNHS-UVJOBNTFSA-N (2s)-1-[(2s)-6-amino-2-[[(1s)-1-carboxy-3-phenylpropyl]amino]hexanoyl]pyrrolidine-2-carboxylic acid;6-chloro-1,1-dioxo-3,4-dihydro-2h-1$l^{6},2,4-benzothiadiazine-7-sulfonamide Chemical compound C1=C(Cl)C(S(=O)(=O)N)=CC2=C1NCNS2(=O)=O.C([C@H](N[C@@H](CCCCN)C(=O)N1[C@@H](CCC1)C(O)=O)C(O)=O)CC1=CC=CC=C1 BFNXYSZBURSNHS-UVJOBNTFSA-N 0.000 description 1
- YKFCISHFRZHKHY-NGQGLHOPSA-N (2s)-2-amino-3-(3,4-dihydroxyphenyl)-2-methylpropanoic acid;trihydrate Chemical compound O.O.O.OC(=O)[C@](N)(C)CC1=CC=C(O)C(O)=C1.OC(=O)[C@](N)(C)CC1=CC=C(O)C(O)=C1 YKFCISHFRZHKHY-NGQGLHOPSA-N 0.000 description 1
- RZTAMFZIAATZDJ-HNNXBMFYSA-N 5-o-ethyl 3-o-methyl (4s)-4-(2,3-dichlorophenyl)-2,6-dimethyl-1,4-dihydropyridine-3,5-dicarboxylate Chemical compound CCOC(=O)C1=C(C)NC(C)=C(C(=O)OC)[C@@H]1C1=CC=CC(Cl)=C1Cl RZTAMFZIAATZDJ-HNNXBMFYSA-N 0.000 description 1
- SFIUYASDNWEYDB-HHQFNNIRSA-N 6-chloro-1,1-dioxo-3,4-dihydro-2h-1$l^{6},2,4-benzothiadiazine-7-sulfonamide;(2s)-1-[(2s)-2-methyl-3-sulfanylpropanoyl]pyrrolidine-2-carboxylic acid Chemical compound SC[C@@H](C)C(=O)N1CCC[C@H]1C(O)=O.C1=C(Cl)C(S(=O)(=O)N)=CC2=C1NCNS2(=O)=O SFIUYASDNWEYDB-HHQFNNIRSA-N 0.000 description 1
- UIYUUEDFAMZISF-FTBISJDPSA-N 6-chloro-1,1-dioxo-3,4-dihydro-2h-1$l^{6},2,4-benzothiadiazine-7-sulfonamide;(2s)-3-methyl-2-[pentanoyl-[[4-[2-(2h-tetrazol-5-yl)phenyl]phenyl]methyl]amino]butanoic acid Chemical compound C1=C(Cl)C(S(=O)(=O)N)=CC2=C1NCNS2(=O)=O.C1=CC(CN(C(=O)CCCC)[C@@H](C(C)C)C(O)=O)=CC=C1C1=CC=CC=C1C1=NNN=N1 UIYUUEDFAMZISF-FTBISJDPSA-N 0.000 description 1
- OZCVMXDGSSXWFT-UHFFFAOYSA-N 6-chloro-1,1-dioxo-3,4-dihydro-2h-1$l^{6},2,4-benzothiadiazine-7-sulfonamide;2-[4-[[4-methyl-6-(1-methylbenzimidazol-2-yl)-2-propylbenzimidazol-1-yl]methyl]phenyl]benzoic acid Chemical compound C1=C(Cl)C(S(=O)(=O)N)=CC2=C1NCNS2(=O)=O.CCCC1=NC2=C(C)C=C(C=3N(C4=CC=CC=C4N=3)C)C=C2N1CC(C=C1)=CC=C1C1=CC=CC=C1C(O)=O OZCVMXDGSSXWFT-UHFFFAOYSA-N 0.000 description 1
- 206010002329 Aneurysm Diseases 0.000 description 1
- 241000185686 Apocynum venetum Species 0.000 description 1
- 201000001320 Atherosclerosis Diseases 0.000 description 1
- 239000004072 C09CA03 - Valsartan Substances 0.000 description 1
- 239000002947 C09CA04 - Irbesartan Substances 0.000 description 1
- 239000002053 C09CA06 - Candesartan Substances 0.000 description 1
- 108090000312 Calcium Channels Proteins 0.000 description 1
- 102000003922 Calcium Channels Human genes 0.000 description 1
- 229940127291 Calcium channel antagonist Drugs 0.000 description 1
- GHOSNRCGJFBJIB-UHFFFAOYSA-N Candesartan cilexetil Chemical compound C=12N(CC=3C=CC(=CC=3)C=3C(=CC=CC=3)C3=NNN=N3)C(OCC)=NC2=CC=CC=1C(=O)OC(C)OC(=O)OC1CCCCC1 GHOSNRCGJFBJIB-UHFFFAOYSA-N 0.000 description 1
- 206010007558 Cardiac failure chronic Diseases 0.000 description 1
- 206010007572 Cardiac hypertrophy Diseases 0.000 description 1
- 208000006029 Cardiomegaly Diseases 0.000 description 1
- GJSURZIOUXUGAL-UHFFFAOYSA-N Clonidine Chemical compound ClC1=CC=CC(Cl)=C1NC1=NCCN1 GJSURZIOUXUGAL-UHFFFAOYSA-N 0.000 description 1
- 206010019280 Heart failures Diseases 0.000 description 1
- FZERHIULMFGESH-UHFFFAOYSA-N N-phenylacetamide Chemical compound CC(=O)NC1=CC=CC=C1 FZERHIULMFGESH-UHFFFAOYSA-N 0.000 description 1
- 206010030113 Oedema Diseases 0.000 description 1
- 208000001647 Renal Insufficiency Diseases 0.000 description 1
- 208000007888 Sinus Tachycardia Diseases 0.000 description 1
- FKNQFGJONOIPTF-UHFFFAOYSA-N Sodium cation Chemical compound [Na+] FKNQFGJONOIPTF-UHFFFAOYSA-N 0.000 description 1
- 208000007718 Stable Angina Diseases 0.000 description 1
- 206010042957 Systolic hypertension Diseases 0.000 description 1
- 108010078660 Vaseretic Proteins 0.000 description 1
- 206010047295 Ventricular hypertrophy Diseases 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 229940092576 accuretic Drugs 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 229940092229 aldactone Drugs 0.000 description 1
- 229960000528 amlodipine Drugs 0.000 description 1
- HTIQEAQVCYTUBX-UHFFFAOYSA-N amlodipine Chemical compound CCOC(=O)C1=C(COCCN)NC(C)=C(C(=O)OC)C1C1=CC=CC=C1Cl HTIQEAQVCYTUBX-UHFFFAOYSA-N 0.000 description 1
- 229910021529 ammonia Inorganic materials 0.000 description 1
- 206010003119 arrhythmia Diseases 0.000 description 1
- 230000006793 arrhythmia Effects 0.000 description 1
- 229940112147 atacand hct Drugs 0.000 description 1
- 229960003515 bendroflumethiazide Drugs 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 description 1
- 102000012740 beta Adrenergic Receptors Human genes 0.000 description 1
- 108010079452 beta Adrenergic Receptors Proteins 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- 239000000480 calcium channel blocker Substances 0.000 description 1
- 229960000932 candesartan Drugs 0.000 description 1
- 229960000830 captopril Drugs 0.000 description 1
- FAKRSMQSSFJEIM-RQJHMYQMSA-N captopril Chemical compound SC[C@@H](C)C(=O)N1CCC[C@H]1C(O)=O FAKRSMQSSFJEIM-RQJHMYQMSA-N 0.000 description 1
- 230000002612 cardiopulmonary effect Effects 0.000 description 1
- 229940083181 centrally acting adntiadrenergic agent methyldopa Drugs 0.000 description 1
- 208000026106 cerebrovascular disease Diseases 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- ANTSCNMPPGJYLG-UHFFFAOYSA-N chlordiazepoxide Chemical compound O=N=1CC(NC)=NC2=CC=C(Cl)C=C2C=1C1=CC=CC=C1 ANTSCNMPPGJYLG-UHFFFAOYSA-N 0.000 description 1
- 229960004782 chlordiazepoxide Drugs 0.000 description 1
- 229960002155 chlorothiazide Drugs 0.000 description 1
- 229960001523 chlortalidone Drugs 0.000 description 1
- JIVPVXMEBJLZRO-UHFFFAOYSA-N chlorthalidone Chemical compound C1=C(Cl)C(S(=O)(=O)N)=CC(C2(O)C3=CC=CC=C3C(=O)N2)=C1 JIVPVXMEBJLZRO-UHFFFAOYSA-N 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 229960002896 clonidine Drugs 0.000 description 1
- 229940000425 combination drug Drugs 0.000 description 1
- 230000008828 contractile function Effects 0.000 description 1
- 210000004351 coronary vessel Anatomy 0.000 description 1
- 229940103463 corzide Drugs 0.000 description 1
- 230000008878 coupling Effects 0.000 description 1
- 238000010168 coupling process Methods 0.000 description 1
- 238000005859 coupling reaction Methods 0.000 description 1
- 230000001934 delay Effects 0.000 description 1
- 230000001627 detrimental effect Effects 0.000 description 1
- 230000000916 dilatatory effect Effects 0.000 description 1
- 229940074620 diovan hct Drugs 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 230000035619 diuresis Effects 0.000 description 1
- 238000002651 drug therapy Methods 0.000 description 1
- 230000002526 effect on cardiovascular system Effects 0.000 description 1
- 239000003792 electrolyte Substances 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 229960003580 felodipine Drugs 0.000 description 1
- 230000006870 function Effects 0.000 description 1
- ZZUFCTLCJUWOSV-UHFFFAOYSA-N furosemide Chemical compound C1=C(Cl)C(S(=O)(=O)N)=CC(C(O)=O)=C1NCC1=CC=CO1 ZZUFCTLCJUWOSV-UHFFFAOYSA-N 0.000 description 1
- 229960003883 furosemide Drugs 0.000 description 1
- 229940083558 furosemide 20 mg Drugs 0.000 description 1
- 238000007429 general method Methods 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- ACGDKVXYNVEAGU-UHFFFAOYSA-N guanethidine Chemical compound NC(N)=NCCN1CCCCCCC1 ACGDKVXYNVEAGU-UHFFFAOYSA-N 0.000 description 1
- 229960003602 guanethidine Drugs 0.000 description 1
- 229940082195 hydrochlorothiazide 12.5 mg Drugs 0.000 description 1
- 229940082205 hydrochlorothiazide 25 mg Drugs 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 229960002198 irbesartan Drugs 0.000 description 1
- YCPOHTHPUREGFM-UHFFFAOYSA-N irbesartan Chemical compound O=C1N(CC=2C=CC(=CC=2)C=2C(=CC=CC=2)C=2[N]N=NN=2)C(CCCC)=NC21CCCC2 YCPOHTHPUREGFM-UHFFFAOYSA-N 0.000 description 1
- 229940088024 isoptin Drugs 0.000 description 1
- 208000017169 kidney disease Diseases 0.000 description 1
- 201000006370 kidney failure Diseases 0.000 description 1
- 230000002045 lasting effect Effects 0.000 description 1
- 229940080157 lexxel Drugs 0.000 description 1
- 229940080255 lopressor hct Drugs 0.000 description 1
- 229940080266 lotensin hct Drugs 0.000 description 1
- 229940080288 lotrel Drugs 0.000 description 1
- 229940072630 maxzide Drugs 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 229960005170 moexipril Drugs 0.000 description 1
- 238000012544 monitoring process Methods 0.000 description 1
- 210000002464 muscle smooth vascular Anatomy 0.000 description 1
- 208000031225 myocardial ischemia Diseases 0.000 description 1
- VWPOSFSPZNDTMJ-UCWKZMIHSA-N nadolol Chemical compound C1[C@@H](O)[C@@H](O)CC2=C1C=CC=C2OCC(O)CNC(C)(C)C VWPOSFSPZNDTMJ-UCWKZMIHSA-N 0.000 description 1
- 229960004255 nadolol Drugs 0.000 description 1
- 230000000955 neuroendocrine Effects 0.000 description 1
- 238000011369 optimal treatment Methods 0.000 description 1
- 230000008816 organ damage Effects 0.000 description 1
- 230000008520 organization Effects 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- 230000002093 peripheral effect Effects 0.000 description 1
- 229940117265 prinzide Drugs 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- KAQKFAOMNZTLHT-OZUDYXHBSA-N prostaglandin I2 Chemical compound O1\C(=C/CCCC(O)=O)C[C@@H]2[C@@H](/C=C/[C@@H](O)CCCCC)[C@H](O)C[C@@H]21 KAQKFAOMNZTLHT-OZUDYXHBSA-N 0.000 description 1
- 229960001455 quinapril Drugs 0.000 description 1
- JSDRRTOADPPCHY-HSQYWUDLSA-N quinapril Chemical compound C([C@@H](C(=O)OCC)N[C@@H](C)C(=O)N1[C@@H](CC2=CC=CC=C2C1)C(O)=O)CC1=CC=CC=C1 JSDRRTOADPPCHY-HSQYWUDLSA-N 0.000 description 1
- 102000005962 receptors Human genes 0.000 description 1
- 108020003175 receptors Proteins 0.000 description 1
- 230000002441 reversible effect Effects 0.000 description 1
- 210000002460 smooth muscle Anatomy 0.000 description 1
- 229910001415 sodium ion Inorganic materials 0.000 description 1
- 229960002256 spironolactone Drugs 0.000 description 1
- 239000013589 supplement Substances 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 229940001587 tarka Drugs 0.000 description 1
- 229940015900 tenoretic Drugs 0.000 description 1
- 229940051105 teveten hct Drugs 0.000 description 1
- 229960001288 triamterene Drugs 0.000 description 1
- 210000005239 tubule Anatomy 0.000 description 1
- 229940054506 uniretic Drugs 0.000 description 1
- 229960004699 valsartan Drugs 0.000 description 1
- SJSNUMAYCRRIOM-QFIPXVFZSA-N valsartan Chemical compound C1=CC(CN(C(=O)CCCC)[C@@H](C(C)C)C(O)=O)=CC=C1C1=CC=CC=C1C1=NN=N[N]1 SJSNUMAYCRRIOM-QFIPXVFZSA-N 0.000 description 1
- 229940032178 vaseretic Drugs 0.000 description 1
- 235000021419 vinegar Nutrition 0.000 description 1
- 239000000052 vinegar Substances 0.000 description 1
- 229940117978 ziac Drugs 0.000 description 1
Landscapes
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
Description
实施例 | 吲哒帕胺的含量(mg/胶囊) | β兼α阻滞剂的含量(mg/胶囊) |
1 | 0.75 | 拉贝洛尔200 |
2 | 1 | 拉贝洛尔250 |
3 | 1.25 | 拉贝洛尔300 |
4 | 1.5 | 拉贝洛尔350 |
5 | 1.75 | 拉贝洛尔400 |
6 | 2 | 拉贝洛尔450 |
7 | 2.25 | 拉贝洛尔500 |
8 | 2.5 | 拉贝洛尔600 |
组别 | 平均剂量mg | 血压mmHg | 治疗结果 | |||
治疗前 | 治疗后 | 达标率% | 有效率% | 无效率% | ||
吲哒帕胺组n=33 | 3.3±0.8 | 161.3±17.6/91.4±5.8 | 138.5±14.8/84.1±6.3 | 40.3 | 72.2 | 27.8 |
拉贝洛尔组n=34 | 812.6±145.5 | 162.9±16.8/92.1±5.6 | 139.7±19.8/85.6±6.4 | 38.7 | 69.8 | 30.2 |
吲哒帕胺+拉贝洛尔复方制剂组n=34 | 2.2±0.5550±125.1 | 162.8±17.3/91.8±5.8 | 127.5±16.1/82.2±7.3 | 67.8 | 85.8 | 14.2 |
P值 | 1:2:3>0.05 | 1:2>0.051:3<0.012:3<0.01 | 1:2>0.051:3<0.012:3<0.01 | 1:2>0.051:3<0.012:3<0.01 | 1:2>0.051:3<0.012:3<0.01 |
组别 | 头痛 | 头晕 | 心动过缓 | 多尿 | 口干 | 低钾血 | 血糖增高 | 总发生率% |
吲哒帕胺组n=33 | 0 | 0 | 0 | 1 | 1 | 0 | 1 | 6 |
拉贝洛尔组n=34 | 1 | 0 | 1 | 0 | 0 | 0 | 0 | 6 |
吲哒帕胺联合拉贝洛尔复方制剂组n=34 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 3 |
P值 | 1:2>0.051:3<0.052:3<0.05 |
实施例 | 吲哒帕胺的含量(mg/胶囊) | β阻滞剂的含量(mg/胶囊) |
10 | 1 | 阿替洛尔10 |
1 | 美托洛尔20 | |
1 | 比索洛尔2 | |
11 | 1.25 | 阿替洛尔12.5 |
1.25 | 美托洛尔25 | |
1.25 | 比索洛尔2.5 | |
12 | 1.5 | 阿替洛尔15 |
1.5 | 美托洛尔30 | |
1.5 | 比索洛尔3 | |
13 | 1.75 | 阿替洛尔17.5 |
1.75 | 美托洛尔35 | |
1.75 | 比索洛尔3.5 | |
14 | 2 | 阿替洛尔20 |
2 | 美托洛尔40 | |
2 | 比索洛尔4 | |
15 | 2.25 | 阿替洛尔22.5 |
2.25 | 美托洛尔45 | |
2.25 | 比索洛尔4.5 | |
16 | 2.5 | 阿替洛尔25 |
2.5 | 美托洛尔50 | |
2.5 | 比索洛尔5 |
组别 | 平均剂量mg | 血压mmHg | 治疗结果 | |||
治疗前 | 治疗后 | 达标率% | 有效率% | 无效率% | ||
吲哒帕胺组n=36 | 3.5±0.9 | 164.4±18.3/89.4±6.8 | 139.8±15.8/83.1±5.3 | 43.3 | 69.2 | 30.8 |
阿替洛尔组n=38 | 50±9.3 | 166.2±15.8/90.8±5.6 | 142.7±16.8/85.1±6.4 | 36.7 | 62.8 | 37.2 |
吲哒帕胺+阿替洛尔复方制剂组n=37 | 1.6±0.316.2±3.1 | 165.8±18.3/90.2±6.8 | 127.4±15.1/81.2±5.3 | 67.8 | 85.8 | 14.2 |
P值 | 1:2:3>0.05 | 1:2>0.051:3<0.012:3<0.01 | 1:2<0.051:3<0.012:3<0.01 | 1:2>0.051:3<0.012:3<0.01 | 1:2>0.051:3<0.012:3<0.01 |
组别 | 头痛 | 头晕 | 乏力 | 心动过缓 | 多尿 | 口干 | 低钾血 | 血糖增高 | 总发生率% |
吲哒帕胺组n=36 | 0 | 0 | 1 | 0 | 1 | 1 | 0 | 0 | 5.5 |
阿替洛尔组n=38 | 1 | 0 | 0 | 2 | 0 | 0 | 0 | 1 | 6.7 |
吲哒帕胺联合阿替洛尔组n=37 | 0 | 1 | 0 | 1 | 0 | 0 | 0 | 0 | 2.7 |
P值 | 1:2>0.051:3<0.052:3<0.05 |
组别 | 平均剂量mg | 血压mmHg | 治疗结果 | |||
治疗前 | 治疗后 | 达标率% | 有效率% | 无效率% | ||
吲哒帕胺组n=33 | 3.4±0.6 | 160.9±16.2/91.2±6.6 | 142.3±17.5/85.1±7.1 | 40.6 | 67.3 | 32.7 |
比索洛尔组n=32 | 7.1±0.6 | 161.5±17.1/91.4±5.8 | 144.2±16.3/86.5±8.2 | 36.7 | 60.9 | 39.1 |
吲哒帕胺+比索洛尔复方制剂组n=33 | 1.8±0.33.6±0.6 | 162.1±18.1/91.7±6.8 | 128.6±16.3/82.4±6.8 | 65.7 | 80.6 | 19.4 |
P值 | 1:2:3>0.05 | 1:2>0.051:3<0.012:3<0.01 | 1:2<0.051:3<0.012:3<0.01 | 1:2>0.051:3<0.012:3<0.01 | 1:2>0.051:3<0.012:3<0.01 |
Claims (8)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN 03150882 CN1225244C (zh) | 2003-09-10 | 2003-09-10 | 含吲哒帕胺和β兼α阻滞剂的复方降压制剂 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN 03150882 CN1225244C (zh) | 2003-09-10 | 2003-09-10 | 含吲哒帕胺和β兼α阻滞剂的复方降压制剂 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN1493282A CN1493282A (zh) | 2004-05-05 |
CN1225244C true CN1225244C (zh) | 2005-11-02 |
Family
ID=34240658
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN 03150882 Expired - Fee Related CN1225244C (zh) | 2003-09-10 | 2003-09-10 | 含吲哒帕胺和β兼α阻滞剂的复方降压制剂 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN1225244C (zh) |
Families Citing this family (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN100384416C (zh) * | 2006-03-20 | 2008-04-30 | 杨军 | 一种用于治疗心血管疾病的药物组合物 |
CN102335129B (zh) * | 2011-08-03 | 2013-06-05 | 天津市嵩锐医药科技有限公司 | 一种供注射用依达拉奉药物组合物及其制备方法 |
-
2003
- 2003-09-10 CN CN 03150882 patent/CN1225244C/zh not_active Expired - Fee Related
Also Published As
Publication number | Publication date |
---|---|
CN1493282A (zh) | 2004-05-05 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN1081460C (zh) | 醛糖还原酶抑制剂用于制备减少与非心脏局部缺血有关的组织损伤的药物的用途 | |
CN1822820A (zh) | 心血管疾病的治疗和预防 | |
CN1237966C (zh) | 一种复方降压制剂 | |
CN1943564A (zh) | 吲达帕胺缓释片及其制备方法 | |
CN1225244C (zh) | 含吲哒帕胺和β兼α阻滞剂的复方降压制剂 | |
CN1245160C (zh) | 含吲哒帕胺和血管紧张素转换酶抑制剂的复方降压制剂 | |
CN1493285A (zh) | 含吲哒帕胺和钙离子拮抗剂的复方降压制剂 | |
CN1237971C (zh) | 含血管紧张素转换酶抑制剂、钙离子拮抗剂和艾司唑仑的复方降压制剂 | |
CN1493284A (zh) | 含吲哒帕胺和血管紧张素ii受体拮抗剂的复方降压制剂 | |
CN1686549A (zh) | 一种治疗高血压的药物组合物 | |
CN1524523A (zh) | 含吲哒帕胺、血管紧张素转换酶抑制剂和螺内酯的复方降压制剂 | |
CN1533277A (zh) | 用于预防或治疗由eNOS表达而引起的疾病的药物 | |
CN101028518A (zh) | 含有硝酸酯类药物和伊伐布雷定的药物组合物 | |
CN1251673C (zh) | 卡托普利控释制剂及其制备方法 | |
CN1899268A (zh) | 苯磺酸左旋氨氯地平滴丸及其制备方法 | |
CN1965933A (zh) | 降压药茶及其制备方法 | |
CN100339072C (zh) | 一种美索巴莫干混悬剂 | |
CN1857726A (zh) | 一种治疗高血压合并高血脂心脑血管疾病的药物组合物 | |
CN101254181B (zh) | 治疗高血压的药物组合物 | |
CN1596896A (zh) | 氨氯地平、厄贝沙坦复方制剂 | |
CN101254182B (zh) | 一种治疗高血压的药物组合物 | |
CN1259912C (zh) | 用于治疗升高的血压的西酞普兰 | |
CN1827103A (zh) | 一种含有依普罗沙坦的药用组合物及其制备方法、用途 | |
CN1102848C (zh) | 一种治疗高血压病的化学药物组合物 | |
CN1695738A (zh) | 一种治疗高血压的药物组合物 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
C14 | Grant of patent or utility model | ||
GR01 | Patent grant | ||
ASS | Succession or assignment of patent right |
Owner name: DU XIAOFENG Free format text: FORMER OWNER: QIDONG GAITIANLI PHARMACEUTICAL CO., LTD. Effective date: 20110803 |
|
C41 | Transfer of patent application or patent right or utility model | ||
C53 | Correction of patent for invention or patent application | ||
CB03 | Change of inventor or designer information |
Inventor after: Xu Nantu Inventor after: Du Xiaofeng Inventor before: Xu Nantu |
|
COR | Change of bibliographic data |
Free format text: CORRECT: ADDRESS; FROM: 226200 NANTONG, JIANGSU PROVINCE TO: 400010 YUZHONG, CHONGQING Free format text: CORRECT: INVENTOR; FROM: XU NANTU TO: XU NANTU DU XIAOFENG |
|
TR01 | Transfer of patent right |
Effective date of registration: 20110803 Address after: 400010, Chongqing, Yuzhong province Jialing East Village No. 49, 2-2 Patentee after: Du Xiaofeng Address before: 226200 No. 88 Heping South Road, Qidong Economic Development Zone, Jiangsu, China Patentee before: Qidong Gaitianli Pharmaceutical Co., Ltd. |
|
CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20051102 Termination date: 20190910 |
|
CF01 | Termination of patent right due to non-payment of annual fee |